This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second look at Phase 2 trial data of Kisqali(ribociclib)
Ticker(s): NVSWho's the expert?
Institution: Weiss Hospital
- Director, Medical Oncology at Weiss Memorial Hospital
- Oncologist whose area of expertise includes breast cancer, lung cancer, lymphoma, genitourinary cancer, and GI cancer
- Currently manages 20 patients with NSCLC
Interview GoalDiscussing new data from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT)
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
